DavidMFriedlandMD
Oncology • Pittsburgh, PAGenitourinary Oncology, Hematologic Oncology, Thoracic Cancer
Medical Oncologist at UPMC
Dr. Friedland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave
3rd Floor
Pittsburgh, PA 15232Phone+1 412-235-1020Fax+1 412-235-1030
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1992 - 1994
Presbyterian Medical Center of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1989 - 1992
University of Maryland School of MedicineClass of 1989
Certifications & Licensure
PA State Medical License 1991 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
- Top MD Consumers Checkbook
Clinical Trials
- Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2000 Mar 01
- Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
- Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma Start of enrollment: 2011 Jul 25
Publications & Presentations
PubMed
- 13 citationsFirst-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLCKaterina Ancevski Hunter, David M. Friedland, Liza C. Villaruz, Timothy F. Burns
Journal of Thoracic Oncology. 2018-01-01 - 14 citationsHigh-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.Tala Achkar, Ananth Arjunan, Hong Wang, Melissa Saul, Diwakar Davar
Plos One. 2017-12-20 - 32 citationsPhase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancerAhmad A. Tarhini, Imran Rafique, Theofanis Floros, Phu Tran, William E. Gooding
Cancer. 2017-08-01
Press Mentions
Timing of Palliative Care Linked to Better Lung Cancer SurvivalOctober 9th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
